ComparisonsUpdated 2026-02-13

AOD-9604 vs Semaglutide: Which Is Better for Weight Loss?

AOD-9604 and semaglutide both target fat loss, but through completely different mechanisms. Semaglutide is a GLP-1 agonist that suppresses appetite centrally, while AOD-9604 is a modified HGH fragment that promotes lipolysis directly. Here's how they stack up. <em>This article is for informational purposes only and is not medical advice.</em>

Comparison Table

FeatureAOD-9604Semaglutide
TypeModified HGH fragment (176-191)GLP-1 receptor agonist
MechanismDirect lipolysis, inhibits lipogenesisAppetite suppression, incretin signaling
Weight LossModest (limited clinical data)15-17% (robust clinical trials)
FDA StatusNot approved (GRAS for food use)FDA approved (Wegovy)
Side EffectsMinimal reportedGI effects (nausea, vomiting)
AdministrationSubcutaneous injectionWeekly subcutaneous injection

How AOD-9604 Works

AOD-9604 is a modified fragment of human growth hormone (amino acids 176-191) with an added tyrosine at the C-terminus. It mimics the fat-burning effects of HGH without the growth-promoting or diabetogenic properties. AOD-9604 stimulates lipolysis (fat breakdown) and inhibits lipogenesis (fat formation) by acting on beta-3 adrenergic receptor pathways.

Unlike HGH, AOD-9604 does not affect IGF-1 levels, blood sugar, or cell proliferation — making it theoretically safer for long-term use. However, clinical weight loss data has been underwhelming compared to expectations.

How Semaglutide Works

Semaglutide suppresses appetite by activating GLP-1 receptors in the hypothalamus, reducing hunger and food intake. It also slows gastric emptying and improves insulin sensitivity. The STEP trials demonstrated 15-17% average weight loss — making it the most effective single-agent anti-obesity drug available.

Beyond weight loss, semaglutide has demonstrated cardiovascular benefits, reduced inflammation, and potential neuroprotective effects.

Head-to-Head: Efficacy

The evidence gap is significant. Semaglutide has multiple large-scale, randomized controlled trials (STEP 1-5, SELECT) demonstrating robust weight loss. AOD-9604's clinical data is much more limited — early trials showed modest fat loss but the peptide never achieved FDA approval for weight management.

Mechanism difference: Semaglutide works centrally (appetite/brain), while AOD-9604 works peripherally (fat tissue). In practice, appetite suppression has proven far more effective for meaningful weight loss than direct lipolysis alone.

Side effects: AOD-9604 has a milder side effect profile. Semaglutide's GI effects (nausea, vomiting) are well-documented, though they typically resolve with titration.

Verdict

For clinically meaningful weight loss, semaglutide is the clear winner with vastly superior evidence and efficacy. AOD-9604 may appeal to those seeking a milder, side-effect-friendly option for modest fat reduction, but expectations should be calibrated accordingly. Some researchers explore combining peripheral and central approaches.

Sourcing

Ascension Peptides offers research-grade AOD-9604 and semaglutide with certificates of analysis and third-party purity verification. Quality matters — always confirm peptide purity before use in research.

Looking for Quality Peptides?

If you're researching peptides, quality sourcing matters. Ascension Peptides offers 99%+ purity with third-party COA testing on every batch.

Explore Ascension Peptides →

Affiliate link — we may earn a commission at no extra cost to you

Frequently Asked Questions

Does AOD-9604 actually work for weight loss?
AOD-9604 has shown fat-reducing effects in preclinical studies, but clinical trial results have been modest. It is not FDA-approved for weight loss and has much weaker evidence than semaglutide.
Can you combine AOD-9604 with semaglutide?
Some practitioners combine peripheral (AOD-9604) and central (semaglutide) approaches. However, this combination is not well-studied. Consult a healthcare provider.
Is AOD-9604 safer than semaglutide?
AOD-9604 appears to have fewer side effects in reported use. However, semaglutide has far more extensive safety data from large clinical trials. "Fewer side effects" does not necessarily mean "safer overall."
Why wasn't AOD-9604 FDA approved?
Phase 2 clinical trials for AOD-9604 showed modest fat loss that was not sufficiently impressive for FDA approval as an anti-obesity drug. It has received GRAS (Generally Recognized As Safe) status for food applications in Australia.

🔬 Looking for quality peptides?

Only buy from suppliers with third-party COA testing.

Ascension Peptides — Verified Supplier →

Affiliate link — we may earn a commission.

Disclaimer: This article is for educational and informational purposes only. It is not medical advice. Peptides mentioned are sold for research purposes only and are not intended for human consumption. Always consult a qualified healthcare provider before making any decisions about supplements or medications.